Boston Scientific CorporationBSXNYSE
Loading
EBITDA Margin Over TimeContracting
Percentile Rank43
3Y CAGR-4.9%
5Y CAGR+4.1%
Year-over-Year Change
EBITDA as a percentage of revenue
3Y CAGR
-4.9%/yr
vs -4.8%/yr prior
5Y CAGR
+4.1%/yr
Recent deceleration
Acceleration
-0.1pp
Decelerating
Percentile
P43
Within normal range
vs 5Y Ago
1.2x
Modest growth
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 18.60% | -20.9% |
| 2024 | 23.51% | -3.0% |
| 2023 | 24.25% | +12.2% |
| 2022 | 21.61% | +2.0% |
| 2021 | 21.18% | +39.0% |
| 2020 | 15.24% | -26.0% |
| 2019 | 20.59% | -21.8% |
| 2018 | 26.32% | +18.6% |
| 2017 | 22.18% | +51.7% |
| 2016 | 14.62% | - |